These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 30214063)

  • 61. GPR56 contributes to the development of acute myeloid leukemia in mice.
    Daria D; Kirsten N; Muranyi A; Mulaw M; Ihme S; Kechter A; Hollnagel M; Bullinger L; Döhner K; Döhner H; Feuring-Buske M; Buske C
    Leukemia; 2016 Aug; 30(8):1734-41. PubMed ID: 27063597
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia.
    Su G; Lian X; Tan D; Tao H; Liu H; Chen S; Yin H; Wu D; Yin B
    Leuk Lymphoma; 2015 Feb; 56(2):472-9. PubMed ID: 24828867
    [TBL] [Abstract][Full Text] [Related]  

  • 63. EVI1 triggers metabolic reprogramming associated with leukemogenesis and increases sensitivity to L-asparaginase.
    Saito Y; Sawa D; Kinoshita M; Yamada A; Kamimura S; Suekane A; Ogoh H; Matsuo H; Adachi S; Taga T; Tomizawa D; Osato M; Soga T; Morishita K; Moritake H
    Haematologica; 2020 Aug; 105(8):2118-2129. PubMed ID: 31649131
    [TBL] [Abstract][Full Text] [Related]  

  • 64. MLL-rearranged acute myeloid leukemia: Influence of the genetic partner in allo-HSCT response and prognostic factor of MLL 3' region mRNA expression.
    Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Carrillo E; Sánchez J; Pérez-López O; Pérez de Soto I; González Campos J; Prats-Martín C; Bernal R; Vargas MT
    Eur J Haematol; 2018 May; 100(5):436-443. PubMed ID: 29384595
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Development of pyrrole-imidazole polyamide targeting fc receptor common gamma chain for the treatment of immune-complex related renal disease.
    Kajiwara M; Ueno T; Fukuda N; Matsuda H; Shimokawa T; Kitai M; Tsunemi A; Fuke Y; Fujita T; Matsumoto K; Matsumoto Y; Ra C; Soma M
    Biol Pharm Bull; 2012; 35(11):2028-35. PubMed ID: 22971693
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetic regulation of the RUNX transcription factor family has antitumor effects.
    Morita K; Suzuki K; Maeda S; Matsuo A; Mitsuda Y; Tokushige C; Kashiwazaki G; Taniguchi J; Maeda R; Noura M; Hirata M; Kataoka T; Yano A; Yamada Y; Kiyose H; Tokumasu M; Matsuo H; Tanaka S; Okuno Y; Muto M; Naka K; Ito K; Kitamura T; Kaneda Y; Liu PP; Bando T; Adachi S; Sugiyama H; Kamikubo Y
    J Clin Invest; 2017 Jun; 127(7):2815-2828. PubMed ID: 28530640
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia.
    Zhou B; Li H; Xing C; Ye H; Feng J; Wu J; Lu Z; Fang J; Gao S
    Biochem Pharmacol; 2017 Mar; 128():12-25. PubMed ID: 28043811
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of MMP-9 transcription and suppression of tumor metastasis by pyrrole-imidazole polyamide.
    Wang X; Nagase H; Watanabe T; Nobusue H; Suzuki T; Asami Y; Shinojima Y; Kawashima H; Takagi K; Mishra R; Igarashi J; Kimura M; Takayama T; Fukuda N; Sugiyama H
    Cancer Sci; 2010 Mar; 101(3):759-66. PubMed ID: 20085585
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors.
    Yadav M; Singh AK; Kumar H; Rao G; Chakravarti B; Gurjar A; Dogra S; Kushwaha S; Vishwakarma AL; Yadav PN; Datta D; Tripathi AK; Chattopadhyay N; Trivedi AK; Sanyal S
    Biochim Biophys Acta; 2016 Oct; 1860(10):2178-90. PubMed ID: 27180173
    [TBL] [Abstract][Full Text] [Related]  

  • 71. RNA binding properties of novel gene silencing pyrrole-imidazole polyamides.
    Iguchi A; Fukuda N; Takahashi T; Watanabe T; Matsuda H; Nagase H; Bando T; Sugiyama H; Shimizu K
    Biol Pharm Bull; 2013; 36(7):1152-8. PubMed ID: 23628892
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family.
    Fears S; Mathieu C; Zeleznik-Le N; Huang S; Rowley JD; Nucifora G
    Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1642-7. PubMed ID: 8643684
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Antitumor effects of pyrrole-imidazole polyamide modified with alkylating agent on prostate cancer cells.
    Funakoshi D; Obinata D; Fujiwara K; Yamamoto S; Takayama K; Hara M; Takahashi S; Inoue S
    Biochem Biophys Res Commun; 2022 Oct; 623():9-16. PubMed ID: 35868070
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
    Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
    Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of alkylating pyrrole-imidazole polyamide conjugates by a novel method for high-throughput sequencer.
    Kashiwazaki G; Maeda R; Kawase T; Hashiya K; Bando T; Sugiyama H
    Bioorg Med Chem; 2018 Jan; 26(1):1-7. PubMed ID: 29224995
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Targeted suppression of metastasis regulatory transcription factor SOX2 in various cancer cell lines using a sequence-specific designer pyrrole-imidazole polyamide.
    Malinee M; Kumar A; Hidaka T; Horie M; Hasegawa K; Pandian GN; Sugiyama H
    Bioorg Med Chem; 2020 Feb; 28(3):115248. PubMed ID: 31879179
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Transcriptional inhibition of progressive renal disease by gene silencing pyrrole-imidazole polyamide targeting of the transforming growth factor-β1 promoter.
    Matsuda H; Fukuda N; Ueno T; Katakawa M; Wang X; Watanabe T; Matsui S; Aoyama T; Saito K; Bando T; Matsumoto Y; Nagase H; Matsumoto K; Sugiyama H
    Kidney Int; 2011 Jan; 79(1):46-56. PubMed ID: 20861821
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Anti-repression of RNA polymerase II transcription by pyrrole-imidazole polyamides.
    Dickinson LA; Trauger JW; Baird EE; Ghazal P; Dervan PB; Gottesfeld JM
    Biochemistry; 1999 Aug; 38(33):10801-7. PubMed ID: 10451376
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Expression of EVI1 in Bone Marrow of Patients with AML and ALL and Its Correlation with Leukemia Subtyping, Clinical Features and Prognosis of Patients].
    Peng DH; Liu J; Hu HN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1323-1329. PubMed ID: 30295245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.